KURA · Kura Oncology, Inc.

Track KURA — free

$12.88 -0.01 (-0.08%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.15B

88.96M

Up next

Next earnings call

Nov 11, 2026 Est · unconfirmed · in 10 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$77.22M

Trailing 12 months

Net income (TTM)

−$296.77M

Trailing 12 months

Revenue growth YoY

+36.5%

Year over year

Operating margin

-411.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-10.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$60.45M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.4%

Year over year · more shares

Price change (1Y)

+63.2%

Trailing year

Short interest

14.8%

Latest settlement · 8.8 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +32%

above

Price vs 50-day avg +18%

above

RSI (14) 64

neutral

MACD trend Positive

52-week position 89%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +36%

trailing

6-month return +40%

trailing

YTD return +24%

this year

Relative strength +27%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $11 › 200d $10 — 50d above 200d

Institutional flow Distributing

-0% holders QoQ · +29 funds added

Insider flow Accumulating

Net +$2.4M over 90 days · 0% sells

Short interest Falling

14.75% of float · ▼ -0.3% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

221 holders — near 3-yr high, broad support

Squeeze score 74

high risk · 0–100

Fundamentals

Fair

Revenue growth +25%

Y/Y

EPS growth −57%

Y/Y

Free cash flow $-70.7M

Balance sheet $139.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 61%

annualized · 1-yr

Max drawdown −39%

past year

ATR 5.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+32% Bullish

Price vs 50-day avg

+18% Bullish

RSI (14)

64 Neutral

MACD trend

Positive Bullish

52-week position

89% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $11 › 200d $10 — 50d above 200d

Institutional flow Distributing

-0% holders QoQ · +29 funds added

Insider flow Accumulating

Net +$2.4M over 90 days · 0% sells

Short interest Falling

14.75% of float · ▼ -0.3% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

221 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $7 Now $13 · 89% Range high $14

vs 200-day avg +32% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
KURA Kura Oncology, Inc. this stock	$1.15B	+24.1%	+25.2%	—	14.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+20.8%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.82B	+6.7%	+20.8%	20.4	2.3%
ARGX Argenx SE	$64.16B	+22.3%	—	—	1.9%
MRNA Moderna, Inc.	$61.59B	+423.1%	+4.3%	—	13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

221

% held: 98.3%
Net QoQ: +2.6M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

181

View

Short & Settlement

Short Interest Falling

Shares short

13.1M

Days to cover: 8.8d
Change: -36.1K sh

View

Short Volume

Short vol %

61%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

967

Value: $9.5K
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

40.2%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$2.4M

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Congressional Trades Buy

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Dec 12, 2022

View

Financials

Revenue (FY)

$67.5M

Net income (FY): $-278.7M
EPS diluted: $-3.18

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 11

View

Proposed Sales

Value

$50.9K

Shares: 4.3K
Filed: Aug 21, 2026

View

Exempt Offerings

Offering

$150.0M

Filed: Feb 5, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
KURA	-5.2%	+36.1%	+39.8%	+1.9%	+24.1%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-4.6%	+37.4%	+27.2%	+2.6%	+12.4%

Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 184 filings 180 filers Visit website Investor relations

KURA · Kura Oncology, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance